Lilly calls time on IDH1/2 inhibition
Servier's vorasidenib had shown promise at ASCO, but Lilly's dual IDH project LY3410738 leaves the pipeline.
Servier's vorasidenib had shown promise at ASCO, but Lilly's dual IDH project LY3410738 leaves the pipeline.
Toxicity casts a shadow over vorasidenib’s prospects as possibly the first targeted therapy for low-grade glioma.